Gaza's Rafah border crossing has reopened but few people get through

KHAN YOUNIS, Gaza Strip (AP) — When the Rafah border crossing between Gaza and Egypt finally reopened this week, Palestinian officials heralded it as a “window of hope” after two years of war as a fragile ceasefire deal moves forward.

But that hope has been sidetracked by disagreements over who should be allowed through, hourslong delays and Palestinian travelers' reports of being handcuffed and interrogated by Israeli soldiers.

Far fewer people than expected have crossed in both directions. Restrictions negotiated by Israeli, Egyptian, Palestinian and international officials meant that only 50 people would be allowed to return to Gaza each day and 50 medical patients — along with two companions for each — would be allowed to leave.

But over the first four days of operations, just 36 Palestinians requiring medical care were allowed to leave for Egypt, plus 62 companions, according to United Nations data. Palestinian officials say nearly 20,000 people in Gaza are seeking to leave for medical care that they say is not available in the war-shattered territory.

Amid confusion around the reopening, the Rafah crossing was closed Friday and Saturday.

The Rafah crossing is a lifeline for Gaza, providing the only link to the outside world not controlled by Israel. Israel seized it in May 2024, though traffic through the crossing was heavily restricted even before that.

Several women who managed to return to Gaza after its reopening recounted to The Associated Press harsh treatment by Israeli authorities and an Israeli-backed Palestinian armed group, Abu Shabab. A European Union mission and Palestinian officials run the border crossing, and Israel has its screening facility some distance away.

Rana al-Louh, anxious to return two years after fleeing to Egypt with her wounded sister, said Israeli screeners asked multiple times why she wanted to go back to Gaza during questioning that lasted more than six hours. She said she was blindfolded and handcuffed, an allegation made by others.

“I told them I returned to Palestine because my husband and kids are there,” al-Louh said. Interrogators told her Gaza belonged to Israel and that “the war would return, that Hamas won’t give up its weapons. I told him I didn’t care, I wanted to return.”

Asked about such reports, Israel's military replied that "no incidents of inappropriate conduct, mistreatment, apprehensions or confiscation of property by the Israeli security establishment are known.”

The Shin Bet intelligence agency and COGAT, the Israeli military body that handles Palestinian civilian affairs and coordinates the crossings, did not respond to questions about the allegations.

The long questioning Wednesday delayed the return to Gaza of al-Louh and others until nearly 2 a.m. Thursday.

Later that day, U.N. human rights officials noted a “consistent pattern of ill-treatment, abuse and humiliation by Israeli military forces.”

“After two years of utter devastation, being able to return to their families and what remains of their homes in safety and dignity is the bare minimum,” Ajith Sunghay, the agency’s human rights chief for the occupied Palestinian territories, said in a statement.

Officials who negotiated the Rafah reopening were clear that the early days of operation would be a pilot. If successful, the number of people crossing could increase.

Challenges quickly emerged. On the first day, Monday, Israeli officials said 71 patients and companions were approved to leave Gaza, with 46 Palestinians approved to enter. Inside Gaza, however, organizers with the World Health Organization were able to arrange transportation for only 12 people that day, so other patients stayed behind, according to a person briefed on the operations who spoke on condition of anonymity because they were not authorized to speak to the media.

Israeli officials insisted that no Palestinians would be allowed to enter Gaza until all the departures were complete. Then they said that since only 12 people had left Gaza, only 12 could enter, leaving the rest to wait on the Egyptian side of the border overnight, according to the person briefed on the operations.

Crossings picked up on the second day, when 40 people were allowed to leave Gaza and 40 to enter. But delays mounted as many returning travelers had more luggage than set out in the agreement reached by negotiators and items that were forbidden, including cigarettes and water and other liquids like perfume. Each traveler is allowed to carry one mobile phone and a small amount of money if they submit a declaration 24 hours ahead of travel.

Each time a Palestinian was admitted to Egypt, Israeli authorities allowed one more into Gaza, drawing out the process.

The problems continued Wednesday and Thursday, with the numbers allowed to cross declining. The bus carrying Wednesday's returnees from the crossing did not reach its drop-off location in Gaza until 1:40 a.m. Thursday.

Still, some Palestinians said they were grateful to have made the journey.

As Siham Omran’s return to Gaza stretched into early Thursday, she steadied herself with thoughts of her children and husband, whom she had not seen for 20 months. She said she was exhausted, and stunned by Gaza’s devastation.

“This is a journey of suffering. Being away from home is difficult,” she said. “Thank God we have returned to our country, our homes, and our homeland.”

Now she shares a tent with 15 family members, using her blouse for a pillow.

Elhennawy reported from Cairo and Geller from New York. Associated Press writer Josef Federman in Jerusalem contributed to this report.

Find more of AP’s coverage at https://apnews.com/hub/israel-hamas-war

Siham Omran, 54, recently returned from Egypt after completing medical treatment, cooks food over a fire beside her tent in Khan Younis, in the southern Gaza Strip, Saturday, Feb. 7, 2026. (AP Photo/Abdel Kareem Hana)

Siham Omran, 54, recently returned from Egypt after completing medical treatment, cooks food over a fire beside her tent in Khan Younis, in the southern Gaza Strip, Saturday, Feb. 7, 2026. (AP Photo/Abdel Kareem Hana)

Rana al-Louh, 45, sits with her granddaughter, Sumaya Abu Suleiman, 3, inside the tent where they live, which had been erected in a schoolyard converted into a shelter in Nuseirat, in the central Gaza Strip, Saturday, Feb. 7, 2026. (AP Photo/Abdel Kareem Hana)

Siham Omran, 54, recently returned from Egypt after completing her medical treatment, looks at the tents of displaced people next to her that were set up in Khan Younis, southern Gaza Strip, Saturday, Feb. 7, 2026. (AP Photo/Abdel Kareem Hana)

Palestinians carry the belongings of relatives arriving in Gaza from Egypt following the long-awaited reopening of the Rafah border crossing, in Khan Younis, southern Gaza Strip, early Thursday, Feb. 5, 2026. (AP Photo/Abdel Kareem Hana)

Palestinians patients and their relatives gather to board a bus in Khan Younis before they head to the Rafah crossing, leaving the Gaza Strip for medical treatment abroad, Wednesday, Feb. 4, 2026. (AP Photo/Abdel Kareem Hana)

RAVENSBURG, Germany--(BUSINESS WIRE)--Sep 28, 2026--

Vetter, a leading Contract Development and Manufacturing Organization (CDMO), continues to expand its commercial fill-and-finish network to further strengthen its global manufacturing operations and support the evolving needs of pharma and biotech customers. The company’s long-term investment program includes the addition of ten more commercial filling lines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928446750/en/

Seven of the ten planned manufacturing lines are being implemented across Vetter’s existing sites. This phased rollout will make additional manufacturing resources available over the coming years. The first new line, designed to fill pre-sterilized syringes, recently became operational, and a second line is expected to follow by the end of 2026. Another five lines for aseptic production are planned through 2028. Looking ahead, the final three lines are planned for Vetter’s new commercial site in Saarlouis, Germany, which is expected to become operational by 2031.

“Pharma and biotech companies seek partners with a proven track record, operational expertise, and the capabilities to support their current and future drug products,” states Managing Director Henryk Badack. “This demand is reflected in our strategy for sustainable growth. Through our ongoing investments, we are expanding our global manufacturing resources and strengthening our ability to support customers throughout the lifecycle of their products in international markets.”

Continued investment in Vetter’s broader operational infrastructure accompanies the expansion of its manufacturing capacity. Current initiatives include expanding compounding, pharmaceutical storage, and visual inspection capabilities, as well as implementing advanced cleanroom technology and increased automation and digitalization.

“Our phased approach enables us to make additional capacity available while systematically expanding our global production network,” explains Managing Director Carsten Press. “These investments provide customers with scalable operations, well-managed supply chains, and high-quality aseptic manufacturing to support their long-term growth.”

Vetter will be exhibiting at CPHI Milan from October 6 to 8, 2026, at booth 6A52, where company representatives will engage with customers and industry stakeholders to discuss current and future project requirements.

Find the Vetter press kit and more background information here.

About Vetter

Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea, and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,400 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.

© Vetter Pharma International GmbH: The latest filling line at Vetter’s commercial facility in Langenargen, Germany